← Back to headlines
Neurocrine Nears $2.5 Billion Acquisition Deal for Soleno Therapeutics
Neurocrine Biosciences is reportedly close to finalizing a deal to acquire Soleno Therapeutics. The potential acquisition is valued at over $2.5 billion, according to reports from the Financial Times.
6 Apr, 02:47 — 6 Apr, 16:10
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (59/100)7 sources33/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left2
Left (2)
Yahoocnbc
Center3
Center (3)
bloombergmarketwatchFT
Right2
Right (2)
wsjseeking-alpha
Far R
Geographic diversity— 2 regions9/34
US6UK1
Sources
Showing 6 of 7 sources
bloombergHigh3h ago
Neurocrine to Buy Soleno Therapeutics for $2.9 Billion - Bloomberg.com
Neurocrine to Buy Soleno Therapeutics for $2.9 Billion Bloomberg.com
Read full article →wsjHigh2h ago
Neurocrine to Buy Soleno for Treatment for Rare Disease That Causes Relentless Hunger - WSJ
Neurocrine to Buy Soleno for Treatment for Rare Disease That Causes Relentless Hunger WSJ
Read full article →FTVery High14h ago
Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment
Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome
Read full article →marketwatchMostly Factual5h ago
Neurocrine wants to develop new obesity drugs. It’s reportedly nearing an acquisition to accelerate that move.
Soleno Therapeutics stock is soaring on Monday in premarket after a report that Neurocrine is nearing a deal to buy the company.
By Jaimy Lee
Read full article →YahooMostly Factual41m ago
Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster
Read full article →seeking-alphaMixed5h ago
Neurocrine to buy Soleno Therapeutics for $53/share in cash
Read full article →Coverage Timeline
First report: FT · 6 Apr, 02:47|Full coverage: 7 · 13h|Window: 13h
Left-leaningCenterRight-leaning
